Is there a positive correlation between tigecycline's price and prescription rate?

How does the price of tigecycline affect its prescription rate?

The relationship between the price of a medication and its prescription rate can be influenced by various factors, including healthcare policies, patient affordability, and competition from alternative treatments. Tigecycline, an intravenous antibiotic used to treat complex skin and soft tissue infections, has experienced fluctuations in its pricing and prescription rate over the years.

What has happened to tigecycline's price?

The price of tigecycline has been subject to patent expiration and generic competition [1]. Initially introduced in 2005, the antibiotic's patent expired in 2015, allowing generic versions to enter the market. This increased competition led to a significant reduction in tigecycline's price, making it more affordable for patients and healthcare providers.

Has the price reduction led to an increase in prescription rates?

Studies suggest that the decreased price of tigecycline has contributed to an increase in its prescription rate [2][3]. A study published in 2019 found that after the introduction of generic tigecycline, the medication's market share increased, and its use became more widespread, particularly in the hospital setting.

Why might the correlation be positive?

Several factors could contribute to the positive correlation between tigecycline's price and prescription rate. Firstly, reduced pricing facilitates better access to the medication, enabling more patients to receive treatment. Secondly, the increased availability of generic tigecycline options may have improved patient affordability, encouraging healthcare providers to prescribe the medication more frequently.

Are there any concerns or limitations to consider?

While the positive correlation between price and prescription rate may be encouraging, it is essential to consider potential limitations and concerns. For instance, the increased usage of tigecycline might lead to antimicrobial resistance, highlighting the need for responsible prescribing practices and antimicrobial stewardship [4].

Sources:

[1] DrugPatentWatch.com: Tigecycline patent expiry

[2] Journal of Antimicrobial Chemotherapy: Generic tigecycline in a US hospital setting

[3] Pharmacoeconomics: Tigecycline generic market share analysis

[4] Clinical Infectious Diseases: Tigecycline and antimicrobial resistance